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AbstrAct
Introduction We investigated the association of the 
proinsulin to insulin ratio (PIR) with prevalent and incident 
type 2 diabetes (T2D), components of the metabolic 
syndrome, and renal and cardiovascular outcomes in the 
population- based Cooperative Health Research in the 
Region of Augsburg (KORA) F4 study (2006–2008)/FF4 study 
(2013–2014).
Research design and methods The analyses included 
1514 participants of the KORA F4 study at baseline and 1132 
participants of the KORA FF4 study after a median follow- up 
time of 6.6 years. All- cause and cardiovascular mortality as 
well as cardiovascular events were analyzed after a median 
time of 9.1 and 8.6 years, respectively. The association 
of PIR with T2D, renal and cardiovascular characteristics 
and mortality were assessed using logistic regression 
models. Linear regression analyses were used to assess 
the association of PIR with components of the metabolic 
syndrome.
Results After adjustment for sex, age, body mass index 
(BMI), and physical activity, PIR was associated with 
prevalent (OR: 2.24; 95% CI 1.81 to 2.77; p<0.001) and 
incident T2D (OR: 1.66; 95% CI 1.26 to 2.17; p<0.001). PIR 
was associated with fasting glucose (β per SD: 0.11±0.02; 
p<0.001) and HbA1c (β: 0.21±0.02; p<0.001). However, 
PIR was not positively associated with other components of 
the metabolic syndrome and was even inversely associated 
with waist circumference (β: −0.22±0.03; p<0.001), BMI (β: 
−0.11±0.03; p<0.001) and homeostatic model assessment 
of insulin resistance (β: −0.22±0.02; p<0.001). PIR was 
not significantly associated with the intima- media thickness 
(IMT), decline of kidney function, incident albuminuria, 
myocardial infarction, stroke, cardiovascular or all- cause 
mortality.
Conclusions In the KORA F4/FF4 cohort, PIR was positively 
associated with prevalent and incident T2D, but inversely 
associated with waist circumference, BMI and insulin 
resistance, suggesting that PIR might serve as a biomarker 
for T2D risk independently of the metabolic syndrome, but 
not for microvascular or macrovascular complications.
InTRoduCTIon
Vascular complications and a roughly doubled 
risk for all- cause mortality pose a great burden 
to patients with type 2 diabetes (T2D).1 
Gerald Reaven suggested that in T2D, insulin 
resistance causes compensatory hyperinsulin-
emia that will lead to the metabolic syndrome 
and finally results in cardiovascular disease.2 
In line, the risk for cardiovascular disease has 
been shown to be doubled in insulin- resistant 
compared with insulin- sensitive individuals 
with pre- diabetes.3
Recently, the awareness for the heteroge-
neity of T2D has increased and efforts have 
been undertaken to define subgroups of T2D 
significance of this study
What is already known about this subject?
 ► Elevated proinsulin may derive from compensatory 
hyperinsulinemia in insulin- resistant states and/or 
from inefficient proinsulin processing or premature 
proinsulin release, indicating an insulin secretion de-
fect. To correct for compensatory hyperinsulinemia, 
the proinsulin to insulin ratio instead of proinsulin 
was suggested. Whether the proinsulin to insulin 
ratio is independently associated with incident type 
2 diabetes and cardiovascular complications is still 
under debate.
What are the new findings?
 ► The proinsulin to insulin ratio was associated with 
an increased risk of incident type 2 diabetes in 
the Cooperative Health Research in the Region 
of Augsburg F4 study (2006–2008)/FF4 study 
(2013–2014).
 ► The proinsulin to insulin ratio was not positive-
ly related to other components of the metabolic 
syndrome and was even inversely associated with 
waist circumference, body mass index and insulin 
resistance.
 ► The proinsulin to insulin ratio was not associat-
ed with the intima- media thickness as measure of 
prevalent subclinical atherosclerosis, nor with car-
diovascular or all- cause mortality.
 ► The proinsulin to insulin ratio was not associated with 
decline of kidney function or incident albuminuria.
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sigificance of this study
How might these results change the focus of research or 
clinical practice?
 ► An elevated proinsulin to insulin ratio is an independent risk factor 
for the development of type 2 diabetes. Due to the lacking or even 
inverse association with other components of the metabolic syn-
drome and anthropometric measures, the proinsulin to insulin ratio 
might be an interesting candidate marker for lean individuals at 
risk for type 2 diabetes. Future research should focus on the ques-
tion whether the proinsulin to insulin ratio represents a prognostic 
marker to identify patients with diabetes at a comparably lower risk 
for diabetes- associated complications.
that may differ in terms of pathophysiology, treatment 
requirements and prognosis. Up to now, T2D was mainly 
regarded as a consequence of obesity- induced insulin 
resistance as part of the metabolic syndrome.4 However, 
lean individuals constitute a substantial proportion of 
patients with T2D and the pathophysiology of T2D in 
this group is still under debate.5 A deeper knowledge on 
the underlying pathophysiology and outcomes of such 
subtypes would enable a more personalized treatment 
and surveillance of patients with T2D. A new concept 
put forward by Ahlqvist et al uses six variables (glutamate 
decarboxylase antibodies, age at diagnosis, body mass 
index (BMI), HbA1c and homeostatic model assessment 
2 estimates of β-cell function and insulin resistance) to 
assign adult- onset T2D into five clusters.6 Among them, 
three clusters mainly include participants with a low BMI: 
cluster 1, referred to as severe autoimmune diabetes 
and characterized by positive glutamate decarboxylase 
antibodies (GAD) antibodies; cluster 2, referred to as 
severe insulin- deficient diabetes (SIDD); and cluster 
5, referred to as mild age- related diabetes. The second 
cluster (SIDD) is characterized by low insulin secretion 
rather than insulin resistance.6 This subtype, according 
to Gerald Reaven, might be less likely to develop cardio-
vascular complications.2
Before the manifestation of diabetes, insulin alone is 
not able to discern healthy insulin- sensitive individuals 
from persons with a defect in insulin secretion as in both 
phenotypes insulin secretion is low. Proinsulin may be a 
marker for a leaner diabetes risk phenotype. Under phys-
iological conditions, virtually all proinsulin is cleaved 
at residues 32–33 and 65–66 to produce C peptide and 
insulin. Only a small amount of intact proinsulin is 
released into the circulation along with the 32–33 split 
proinsulin and the 65–66 split proinsulin.7 Hyperproin-
sulinemia indicates a pathological state that may arise 
from inefficient proinsulin processing within the β-cell 
secretory granula or the premature release of proinsulin.8
Because high proinsulin secretion also appears along 
with high insulin secretion in compensatory hyperinsu-
linemia, the proinsulin to insulin ratio (PIR) is used to 
differentiate disproportionally elevated proinsulin from 
compensatory hyperinsulinemia. Several studies have 
shown that a high PIR indicates disturbed insulin secre-
tion.9–11 PIR has been connected to a primary defect in 
insulin secretion already in healthy individuals12 and 
associates with T2D in a prospective manner.13–17 Hence, 
PIR appears to be suitable to detect insulin deficiency 
already before the onset of T2D.
Our hypothesis was that PIR is associated with preva-
lent and incident T2D, but not with other components 
of the metabolic syndrome, the intima- media thick-
ness (IMT) as marker for prevalent subclinical athero-
sclerosis,18 or cardiovascular or renal events in the 
population- based Cooperative Health Research in the 
Region of Augsburg (KORA) F4 study (2006–2008)/
FF4 study (2013–2014).
MeTHods
study participants and definition of variables
The KORA F4 (2006–2008) and FF4 (2013–2014) cohort 
studies are follow- up examinations of the population- 
based KORA S4 study (1999–2001). Recruitment and 
eligibility criteria for the KORA studies, study design, stan-
dardized sampling methods and data collection (medical 
history, medication, anthropometric and blood pressure 
measurements) have been described elsewhere.19 20 All 
participants gave written informed consent before taking 
part. Total proinsulin was measured in the first 1567 
participants of the KORA F4 study. Participants with a 
diabetes type other than type 2 or unknown glucose toler-
ance status (n=25) and participants with T2D treated 
with insulin (n=28) were excluded from the analyses. 
Of the remaining 1514 participants, 66 died before the 
follow- up examination and 316 declined participation in 
the FF4 survey or could not be contacted. After exclu-
sion of participants with prevalent T2D in the baseline 
examination (n=91), the study sample in the longitudinal 
F4/FF4 examination comprised 1001 participants for the 
analysis of incident T2D. Participants with missing covari-
ates for other outcomes were excluded from the respec-
tive analyses. The numbers of participants included in 
each analysis are given in the results tables and illustrated 
in online supplementary figure 1. The median (first quar-
tile; third quartile) follow- up time was 6.6 (6.4; 6.8) years.
Criteria for a clinically diagnosed diabetes mellitus were 
a validated medical diagnosis or current self- reported use 
of glucose- lowering agents. After an overnight fasting 
period, all participants without clinically diagnosed 
diabetes underwent a standard 75 g oral glucose toler-
ance test. Newly diagnosed diabetes, impaired glucose 
tolerance (IGT), impaired fasting glucose (IFG), and 
normal glucose tolerance (NGT) were defined according 
to the 1999 WHO diagnostic criteria based on both fasting 
and postchallenge glucose values (T2D: ≥7.0 mmol/L 
fasting and/or ≥11.1 mmol/L 2- hour glucose; IFG: 
≥6.1 and <7.0 mmol/L fasting glucose; IGT: ≥7.8 and 
<11.1 mmol/L 2- hour glucose). Pre- diabetes was defined 
as IFG and/or IGT.
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Metabolic syndrome was defined according to the Inter-
national Diabetes Federation definition as presence of at 
least three of the following five criteria: (1) elevated waist 
circumference (waist circumference ≥94 cm in men and 
≥80 cm in women); (2) fasting triglycerides ≥1.7 mmol/L 
and/or use of fibrates or nicotinic acid; (3) high- density 
lipoprotein (HDL) cholesterol <1.0 mmol/L in men or 
<1.3 mmol/L in women and/or use of fibrates or nico-
tinic acid; (4) fasting glucose ≥5.6 mmol/L and/or use of 
glucose- lowering medication; (5) elevated blood pressure 
(systolic blood pressure ≥130 mm Hg and/or diastolic 
blood pressure ≥85 mm Hg and/or use of antihyperten-
sive medication, given that the participants were aware of 
being hypertensive).
Arterial hypertension was defined as a systolic blood 
pressure ≥140 mm Hg and/or a diastolic blood pressure 
≥90 mm Hg, and/or intake of antihypertensive medi-
cation, given that the participants were aware of being 
hypertensive.
Leisure time physical activity was assessed with two sepa-
rate questions concerning leisure time sport activity in 
winter and in summer (cycling included). Possible answers 
were: (1) >2 hours, (2) 1–2 hours, (3) <1 hour, and (4) none 
per week. Participants who had a total score <5, obtained 
by summing the numbers (1)–(4) from the winter and 
summer questions, were classified as ‘physically active’.
Total mortality and cardiovascular mortality (Inter-
national Classification of Diseases Ninth Revision codes 
390–459 and 798) were ascertained by regularly checking 
the vital status of the participants through the popula-
tion registries. Death certificates were obtained from the 
local health authorities. Incident non- fatal myocardial 
infarction occurring until the age of 75 years was assessed 
by surveillance through the local myocardial infarction 
registry. Incident non- fatal myocardial infarction occur-
ring in participants >74 years or residing outside the study 
area, as well as non- fatal stroke were assessed by postal 
follow- up questionnaires. Using data from participants’ 
hospital records and their attending physicians, all self- 
reported incident stroke cases and myocardial infarction 
cases occurring outside the study area or in persons >74 
years and the date of diagnosis were validated. Stroke and 
myocardial infarction were pooled to a combined end 
point with the only first event taken into account in case 
of several events. Participants with prevalent stroke (n=34) 
or prevalent myocardial infarction (n=41) or missing data 
on incident stroke and myocardial infarction (n=84) were 
excluded from the analyses regarding the outcome of inci-
dent myocardial infarction or stroke. The follow- up time 
(median (first quartile; third quartile)) was 9.1 (8.8; 9.4) 
years for total and cardiovascular mortality and 8.6 (8.1; 
9.0) years for incident stroke/myocardial infarction.
Laboratory measurements
Blood samples were collected after an overnight fast of 
at least 8 hours and were kept at room temperature until 
centrifugation. Plasma was separated immediately, serum 
after 30 min. Plasma and serum samples were assayed 
immediately or stored at −80°C. Blood glucose levels 
were assessed using the hexokinase method (GLU Flex; 
Dade Behring, Marburg, Germany). HDL cholesterol was 
measured with enzymatic methods (CHOD- PAP; Dade 
Behring). Triglycerides were measured by an enzymatic 
color test (GPO- PAP method, TGL Flex; Dade Behring). 
Serum creatinine was determined with a modified Jaffe 
test (Krea Flex; Dade Behring). Insulin was measured 
by an electrochemiluminescence immunoassay on a 
Cobas e602 instrument (Roche Diagnostics, Mannheim, 
Germany). HbA1c was measured in hemolyzed whole 
blood using the cation- exchange high- performance 
liquid chromatographic, photometric VARIANT II 
TURBO HbA1c Kit—2.0 assay on a VARIANT II TURBO 
Hemoglobin Testing System (Bio- Rad Laboratories, 
Hercules, USA). Intact proinsulin (frozen EDTA plasma) 
was measured by ELISA (intact human proinsulin ELISA, 
Cat No EZHIPI- 17K, Linco Research, St Charles, MO). 
Estimated glomerular filtration rate (eGFR) was calcu-
lated using the Chronic Kidney Disease Epidemiology 
Collaboration equation (2009) based on serum creat-
inine.21 Homeostatic model assessment of insulin resis-
tance (HOMA- IR) was calculated as fasting insulin (in 
pmol/L)×fasting glucose (in mmol/L)÷135 in all partici-
pants except those with antidiabetic treatment.
Measurement of IMT
Ultrasound measurement (Sonoline G, 10 MHz trans-
ducer; Siemens Medical Solutions, Munich, Germany) 
of both common carotid arteries (CCA) was performed 
using a validated protocol22 as previously described.23 
Optimal images of the right and left CCAs far wall were 
recorded on DVD videotapes. IMT measurements were 
performed off line over a length of 10 mm beginning at 
0–5 mm of the dilatation of the distal CCA using an auto-
mated edge detection reading system (Prowin software, 
Medical Technologies International, USA). We used the 
average of the measurements of three frozen images from 
both the left and right CCAs to calculate artery thick-
ness of the distal CCA ((mean left+mean right)/2). One 
certified reader measured all IMT scans. Reproducibility 
studies for intersonographer (n=30 IMT measurements) 
and inter- reader variability (n=50 IMT measurements) 
revealed coefficients of variations of 1.9% and 3.0% with 
Spearman correlation coefficients of ≥0.89.
statistical analyses
Characteristics of the study participants were compared 
between participants with NGT and with pre- diabetes or 
T2D, respectively, using t- tests in case of approximately 
normally distributed variables. Mann- Whitney U tests 
were performed for variables with skewed distributions. 
Binomial proportions were compared with χ2 tests. The 
associations of PIR with the outcomes of interest were 
assessed in logistic regression models in case of categor-
ical dependent variables and in linear regression models 
in case of continuous dependent variables. Continuous 
variables were transformed to a Gaussian distribution by 
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the probability integral transformation followed by an 
inverse transform sampling and were used as in calcu-
lations per 1 SD. In multivariable logistic and linear 
regression analyses, the associations of PIR with the 
respective dependent variables were adjusted for covari-
ates in different models: model 1: age (continuous), sex 
and physical activity (active/inactive); model 2: model 1 
plus BMI (continuous); model 3: model 2 plus arterial 
hypertension. Smoking status (never/former/current), 
alcohol consumption (no; moderate (men 0.1 to <40 g/
day and women 0.1 to <20 g/day); high (men ≥40 g/day 
and women ≥20 g/day/high)), low- density lipoprotein, 
HDL and triglycerides were not found to be associated 
with PIR after adjustment for sex, age and BMI and were 
therefore not included in the models. Pre- existing cases 
at baseline were excluded from the longitudinal inci-
dence analyses. The level of statistical significance was 
set at 5% (two sided). The calculations were performed 
using the statistical environment R, V.3.6.0.
ResuLTs
study population characteristics
Table 1 displays the baseline characteristics of the total 
study population and stratified by diabetes status. PIR was 
higher in participants with T2D (p<0.001). Baseline char-
acteristics of participants who progressed to T2D during 
the follow- up time versus non- progressors are shown in 
online supplementary table 1. PIR was elevated in partic-
ipants who developed incident T2D in comparison to 
non- progressors (p<0.001).
Association of PIR with T2d and glycemic traits
An increased PIR was associated with a higher T2D prev-
alence (OR per SD 2.24; 95% CI 1.81 to 2.77), a higher 
T2D incidence (OR: 1.66; 95% CI 1.26 to 2.17), and with 
incident pre- diabetes after adjustment for sex, age, BMI 
and physical activity (table 2).
Cross- sectionally, PIR was directly related to HbA1c and 
fasting glucose (table 3). Interestingly, PIR was inversely 
associated with HOMA- IR. This inverse association was 
present in normoglycemic, pre- diabetic and diabetic 
participants with the weakest association in pre- diabetic 
individuals (online supplementary table 2).
Proinsulin alone was strongly associated with prevalent 
(OR 4.15; 95% CI 3.14 to 5.48) and incident T2D (OR 
3.72; 95% CI 2.55 to 5.42) after adjustment for sex, age, 
BMI and physical activity.
Association of PIR with components of the metabolic 
syndrome and BMI
In linear regression analysis with the components of the 
metabolic syndrome (table 4), PIR was directly associ-
ated with elevated fasting glucose and inversely associ-
ated with an elevated waist circumference. In line, PIR 
was inversely associated with BMI after adjustment for 
sex, age and physical activity (β: −0.11±0.03; p<0.001). 
PIR was not associated with the other components of the 
metabolic syndrome (elevated blood pressure, elevated 
triglycerides, and reduced HDL cholesterol) after adjust-
ment for sex, age and physical activity.
In contrast, proinsulin alone was strongly directly asso-
ciated with all components of the metabolic syndrome 
(online supplementary table 3).
Lack of an association of PIR with IMT, decline of renal 
function, cardiovascular events, cardiovascular mortality and 
all-cause mortality
Cross- sectionally, PIR was not significantly associated with 
IMT after adjustment for sex, age, BMI, arterial hyperten-
sion and physical activity (online supplementary table 4). 
In the longitudinal analysis, PIR was not associated with 
the incidence of a urinary albumin to creatinine ratio 
≥30 mg/g and of an eGFR <60 mL/min/1.73 m² (online 
supplementary table 5). Further, an increased PIR was 
not related to the combined cardiovascular end point 
comprising non- fatal and fatal myocardial infarctions 
and stroke, nor to cardiovascular or all- cause mortality 
(table 5).
The association of proinsulin alone with IMT (online 
supplementary table 4), decline of kidney function and 
incident albuminuria (online supplementary table 5), 
the combined cardiovascular end point, cardiovascular 
mortality and all- cause mortality (online supplementary 
table 6) were stronger in the crude analyses (p<0.001 for 
each observation) compared with the associations of PIR 
with the respective parameters. However, significance of 
these associations disappeared after multivariable adjust-
ment, except for all- cause mortality, which remained 
significantly associated with proinsulin (HR 1.35; 95% CI 
1.07 to 1.70; p=0.012).
dIsCussIon
In the population- based KORA F4/FF4 cohort, we 
showed that the PIR is positively associated with preva-
lent and incident T2D, but not with other components 
of the metabolic syndrome. In cross- sectional analyses 
we observed an association of PIR with HbA1c, fasting 
glucose and T2D. A further recent cross- sectional study by 
Nakamura et al described an association of fasting proin-
sulin with fasting glucose and T2D that was stronger than 
the association of PIR and the proinsulin to C peptide 
ratio.24 We confirmed a stronger association of proin-
sulin alone compared with PIR with prevalent and inci-
dent T2D. Nonetheless, PIR was independently related 
to a higher risk for incident pre- diabetes and T2D in 
our study. These results are in line with previous studies 
describing an association of PIR with incident T2D.13–17 
However, other studies found no association of PIR with 
incident diabetes.25–27 These divergent findings might be 
explained by the shorter follow- up time of 24 months in 
the Hoorn study25 and the lower incidence of T2D in the 
study of Wareham et al.26
Interestingly, PIR associated inversely with HOMA- IR 
and anthropometric measures (BMI and waist circum-
ference) in our study cohort, which fits the hypothesis 
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Table 2 ORs (95% CI) for prevalent pre- diabetes (vs normal glucose tolerance) and type 2 diabetes (vs no type 2 diabetes), 
as well as with incident pre- diabetes (vs non- progressors to pre- diabetes) and incident type 2 diabetes (vs non- progressors 
to type 2 diabetes) as dependent variables and proinsulin to insulin ratio as independent variable (per SD): results of logistic 
regression models
Prevalent pre- diabetes
(yes: n=275; no: n=1091)
Prevalent type 2 diabetes
(yes: n=148; no: n=1366)
Incident pre- diabetes
(yes: n=135; no: n=677)
Incident type 2 diabetes
(yes: n=79; no: n=922)
Without adjustment
1.23 (1.07 to 1.40)** 2.26 (1.87 to 2.73)*** 1.24 (1.03 to 1.50)* 1.58 (1.24 to 2.01)***
Adjustment for sex, age, BMI, physical activity (model 2)
1.10 (0.94 to 1.29) 2.24 (1.81 to 2.77)*** 1.27 (1.03 to 1.57)* 1.66 (1.26 to 2.17)***
*p<0.05; **p<0.01; ***p<0.001.
BMI, body mass index.
Table 3 Cross- sectional association estimates between 
proinsulin to insulin ratio and continuous glycemic traits: β 
coefficients±SE from linear regression models are given per 
SD proinsulin to insulin ratio












Adjustment for sex, age, BMI, physical activity (model 2)
0.21±0.02*** 0.11±0.02*** −0.22±0.02***
***p<0.001.
BMI, body mass index; HOMA- IR, homeostatic model assessment 
of insulin resistance.
Table 4 Cross- sectional association estimates between 
proinsulin to insulin ratio and components of the metabolic 
syndrome adjusted for sex, age and physical activity (model 
1): β coefficients±SE from linear regression models are 
given per SD
Adjusted β±SE P value
Elevated waist circumference*
(yes: n=1011; no: n=503)
−0.22±0.03 <0.001
Elevated triglycerides†
(yes: n=371; no: n=1143)
0.08±0.08 0.21
Reduced HDL cholesterol‡
(yes: n=276; no: n=1238)
−0.08±0.07 0.23
Elevated fasting glucose§
(yes: n=463; no: n=1051)
0.30±0.06 <0.001
Elevated blood pressure¶
(yes: n=740; no: n=774)
0.03±0.06 0.62
*Defined as ≥80 cm in women and ≥94 cm in men.
†Defined as ≥1.7 mmol/L and/or intake of fibrates or nicotinic acid.
‡Defined as <1.0 mmol/L in men and <1.3 mmol/L in women and/
or intake of fibrates or nicotinic acid.
§Ddefined as ≥5.6 mmol/L and/or intake of antidiabetic 
medication.
¶Defined as systolic blood pressure ≥130 mm Hg and/or diastolic 
blood pressure ≥85 mm Hg and/or use of antihypertensive 
medication, given that the participants were aware of being 
hypertensive.
HDL, high- density lipoprotein.
of an insulin- deficient T2D subtype that constitutes a low 
HOMA- IR (normal to high insulin sensitivity), but a high 
PIR (defect in insulin secretion). Our observation of an 
association of PIR with glucose metabolism that is inde-
pendent of the metabolic syndrome is supported by a 
recent study showing increased proinsulin secretory ratios 
in non- obese participants with T2D compared with obese 
participants with T2D in response to a glucose- potentiated 
arginine test.28 In turn, high HOMA- IR, indicating insulin 
resistance (eg, in overweight or obesity), may initially be 
related to a low PIR in pre- diabetes or NGT, resulting 
from a compensatory hypersecretion of insulin, whereas 
proinsulin levels initially remain constant, leading to a 
decreased or normal PIR.17 29 30 At a later stage, when β-cell 
failure and T2D become apparent, proinsulin levels will 
increase disproportionately, resulting in an elevated PIR. 
Hence, for insulin- resistant individuals, an elevated PIR 
may be found in manifest T2D, but not in pre- diabetes. 
In line, in our study, PIR was strongly elevated in diabetic 
participants, but was not associated with prevalent pre- 
diabetes in the regression analysis. Interestingly, however, 
PIR was associated with incident pre- diabetes, indicating 
that the underlying β-cell defect may be detectable in a 
very early stage before the progression to pre- diabetes, 
when insulin resistance- driven hyperinsulinemia might 
temporarily obscure the association. In line, the inverse 
association between PIR and HOMA- IR was present in all 
glucose tolerance groups, but was lowest in participants 
with pre- diabetes, constituting the group with the highest 
proportion of primarily insulin- resistant participants with 
high insulin levels and preserved β-cell function with 
relatively low proinsulin levels. In contrast to our results, 
two recent cross- sectional studies found a positive asso-
ciation of PIR with HOMA- IR in diabetic participants31 
and in obese Egyptians.32 However, these results were not 
corrected for possible confounders.
Apart from the direct association with elevated fasting 
glucose and the inverse association with an elevated 
waist circumference, PIR was not related to the other 
components of the metabolic syndrome, namely elevated 
triglycerides, reduced HDL cholesterol and elevated 
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Table 5 HRs (95% CI) for overall mortality, cardiovascular mortality, non- fatal and fatal stroke, and non- fatal myocardial 
infarction or coronary death in dependence on proinsulin to insulin ratio (per SD)
All- cause mortality Cardiovascular mortality
Non- fatal or fatal stroke, myocardial 
infarction, or coronary death
n (non- cases)† 1391 1459 1262
n (cases)‡ 123 55 93
Without adjustment
Total study cohort 1.57 (1.31 to 1.88)*** 1.74 (1.33 to 2.27)*** 1.33 (1.09 to 1.63)**
Adjustment for sex, age, BMI, arterial hypertension, physical activity (model 3)
Total study cohort 1.16 (0.96 to 1.42) 1.22 (0.90 to 1.64) 1.01 (0.81 to 1.26)
**p<0.01; ***p<0.001.
†Number of participants without events.
‡Number of events.
BMI, body mass index.
blood pressure, which is in line with a study by Pivatto 
et al showing that proinsulin and insulin alone, but not 
PIR, were associated with the metabolic syndrome.33 In 
sum, these data indicate that the diabetes risk phenotype 
with an increased PIR is not primarily characterized by 
obesity, the metabolic syndrome, or insulin resistance.
Despite the increased risk of prevalent and incident 
T2D, PIR was not associated with IMT, incident albu-
minuria ≥30 mg/g creatinine, decline of kidney function 
below an eGFR of 60 mL/min/1.73 m² and cardiovascular 
events and mortality even without adjustment for glucose 
tolerance status. This is in line with the literature on PIR 
and diabetic complications.34 35 It has to be noted that 
several studies found an association between proinsulin 
itself and cardiovascular complications.36–39 However, 
as outlined above, only PIR is corrected for an insulin 
resistance- driven hyperinsulinemia, whereas proin-
sulin alone will increase with increasing HOMA- IR.40 
Thus, proinsulin is associated with insulin resistance,41 
which may partly explain the association of proinsulin 
with cardiovascular events and mortality,42 since a high 
HOMA- IR has been shown to predict cardiovascular 
disease.43 Consequently, proinsulin alone may be asso-
ciated with cardiovascular disease, but only PIR is suit-
able to detect a more insulin- sensitive but insulinopenic 
subtype of T2D risk, which possibly does not confer as 
strongly an increased risk for cardiovascular complica-
tions as the insulin- resistant T2D subtype. In our study, 
proinsulin alone was associated with all- cause mortality 
after multivariable adjustment, whereas the associations 
with IMT, the combined cardiovascular end point and 
cardiovascular mortality, which were highly significant in 
the crude analyses, lost significance after multivariable 
adjustment, supporting the view that proinsulin is not an 
independent cardiovascular risk factor in the KORA F4 
cohort.
In a recent cross- sectional study, PIR was higher in 
participants with diabetic nephropathy compared with 
diabetic participants without nephropathy.31 However, 
long- standing T2D may provoke higher PIR irrespective 
of the underlying pathophysiology (insulin deficient vs 
insulin resistant), and a higher PIR in that study does not 
necessarily point to a more insulin- sensitive phenotype 
anymore. In insulin- resistant individuals with overt T2D, 
PIR might mainly indicate severity of dysglycemia, which 
probably is connected to nephropathy, and the study did 
not consider these possible confounders.
strengths and limitations
The findings of our study are based on a large and 
well- characterized prospective study. Glucose tolerance 
status was determined by oral glucose tolerance test at 
baseline and follow- up visits. However, the KORA study 
included nearly exclusively Caucasians. Hence, our 
results may not apply to other ethnic groups. We used 
HOMA- IR instead of the gold standard methods (ie, 
hyperinsulinemic- euglycemic clamp) to measure insulin 
resistance. However, HOMA- IR is a widely used marker 
and can be considered as a reliable index for insulin 
resistance for clinical research purposes.44 The follow- up 
time for mortality and cardiovascular events was about 
9 years. With a mean age of 56 years at baseline, cardio-
vascular events might occur at a higher age and there-
fore a longer follow- up time might be necessary. In sum, 
123 deaths (about 8% of the cohort) and 93 first cardio-
vascular events were reported in this study. We cannot 
exclude that, with a longer follow- up time, we would have 
detected further events, which might have altered some 
of our results.
ConCLusIon
In conclusion, our results support the notion that PIR 
is elevated in a T2D risk subphenotype that is character-
ized by lower BMI and higher insulin sensitivity and that 
does not confer a higher rate of renal or cardiovascular 
events. Future studies focusing on lean individuals at 
high risk for T2D should further examine the value of 
PIR as prospective biomarker for incident pre- diabetes, 
T2D and secondary complications.
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